<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01924221</url>
  </required_header>
  <id_info>
    <org_study_id>RER CRT</org_study_id>
    <secondary_id>NA_00065477</secondary_id>
    <nct_id>NCT01924221</nct_id>
  </id_info>
  <brief_title>Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy</brief_title>
  <acronym>RER CRT</acronym>
  <official_title>Study of Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronization therapy with pacemaker alone, or in combination with a
      cardioverter-defibrillator, prolongs life and decreases risk of heart failure exacerbation
      in patients with low ejection fraction and wide QRS. Some patients achieve decrease in QRS
      duration 6 months after cardiac resynchronization therapy. Such fenomenon is called reverse
      electrical remodeling of native conduction. Retrospective analysis showed that reverse
      electrical remodeling of the native conduction after at least 6 months of CRT is associated
      with decreased rate of ventricular arrhythmias and better survival. This study is designed
      to study  reverse electrical remodeling prospectively.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Sustained ventricular tachyarrhythmias</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Hospitalizations</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Heart Failure.</condition>
  <condition>An Approved Indication Per ACC/AHA/HRS Guidelines for Implantation of a Cardiac Resynchronization Therapy Defibrillator</condition>
  <arm_group>
    <arm_group_label>CRT</arm_group_label>
    <description>Patients with implanted cardiac resynchronization therapy defibrillator</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>this is an observational study. No intervention</intervention_name>
    <arm_group_label>CRT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Heart Failure Patients with currently approved indications for implantation of cardiac
        resynchronization therapy defibrillator
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  an approved indication per ACC/AHA/HRS guidelines for implantation of a CRT-D

        Exclusion Criteria:

          -  age &lt; 18 y

          -  pregnancy or planned pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 14, 2013</lastchanged_date>
  <firstreceived_date>August 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Larisa Tereshchenko</investigator_full_name>
    <investigator_title>Instructor of Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
